February 24, 2021 7:46am
Beat-down shares still have today’s Q4 and FY20 earnings’ releases to deal with
Pre-open indication: 6 BUY and 3 SELLs
Today’s Q4 & FY20 earnings’ releases: Ionis Pharmaceuticals (IONS), Vericel (VCEL), Sangamo Therapeutics (SGMO), Sage Therapeutics (SAGE), Global Blood Therapeutics (GBT);
Companies mentioned: AGTC, BSTG, BLUE, CRSP, MESO, NTLA, PSTI, SLDB and SAGE
What I provide is a trusted source of share pricing intelligence that ensures that investors are kept apprised of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets
Dow futures are DOWN -0.21% (-65 points), S&P futures are DOWN -0.21% (-8 points) and NASDAQ futures are DOWN -0.72% (-95 points)
Futures are down and moving lower early Wednesday;
European stocks inched higher as the pan-European Stoxx 600 gained 0.4% by late morning trade;
Asia-Pacific shares were mostly lower as caution undermined markets
Data Docket: Total mortgage application volume fell 11.4% compared with the previous week, according to the Mortgage Bankers Association's seasonally adjusted index. ... seasonally adjusted index. The average contract interest rate for 30-year fixed-rate mortgages increased to 3.08% from 2.98% last week.
Henry’omics:
Quite a few earnings’ releases today for the cell and gene therapy sector as …
Fed Chair Powell’s visit to Capitol Hill will continue when he addresses the House of Representatives Financial Services Committee. Investors will also get another look at the construction industry with data on new home sales and an earnings report from Lowe’s.
Today’s Q4 & FY20 earnings’ releases: Wednesday, 2/24 - Ionis Pharmaceuticals (IONS), Vericel (VCEL), Sangamo Therapeutics (SGMO), Sage Therapeutics (SAGE), Global Blood Therapeutics (GBT);
Thursday, 2/25 - Caladrius Biosciences (CLBS), Editas Medicine (EDIT), Voyager Therapeutics (VYGR), Intellia Therapeutics (NTLA)
Coming attractions: earnings’ releases – Monday, 3/1 - Precigen (PGEN), Adverum Biotechnologies (ADVM) and Regenxbio (RGNX)
Tuesday’s evening’s recap: “a pullback, a reversal, a retest or in many cases just plain old earnings’ season doldrums? Based on continuing weakness, pricing elasticities and badly conceived price targets.” … https://www.regmedinvestors.com/articles/11783
- The Nasdaq closed DOWN -67.85 points (-0.50%);
- The IBB closed down -1.40% and XBI closed down -2.24%;
- Sector volume was LOW with 4 of the 8-upside having higher than the 3-month average volume with the increased volume of 15 of 26-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was up +0.34 points or +1.45% at 23.11;
- Tuesday’s percentage (%) of the 8-upside were +0.20% (IONS) to +41.78% (SLDB) while the 26-downside ranges from -0.33% (QURE) to -16.14% (CLBS);
February: 8 positive, 8 negative closes and 1 holiday to date
January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
Maintaining Sell: Questions continue …
Biostage (BSTG) closed down -$0.20 to $1.80 with 4,062 shares traded after Monday’s +$0.145 to $2.00 with 2,094 shares traded, Friday’s -$0.00 to $1.85 with only 23 shares traded (interesting how no share traded without the “pumping of buys”, Thursday’s -$0.115 to $1.85 with 303 shares traded and last Wednesday’s -$0.12 to $1.97 with 4.656 shares traded. Reiterating …
Question#1: WHERE is all the money from DST Capital going or even coming FROM – “to pump the public share price”? just think over the past months if those dollars were put into the company coffers, they wouldn’t be cutting back on employees’ salaries – also WHAT did they take PPP funds for or MAYBE a clinical trial would have been initiated?
Question#2: WHAT is the relationship of DST Capital beyond being BSTG’s investor as they are BOTH based in the same offices – together. WHY is Dixintong Technology Group in Beijing, China led by Donghai Lui defining BSTG’s path forward as Hong Yu, BSTG’s president reports to him through Jason Chen, BSTG’s chairman who also reports to him while managing DST Capital, bottom-line his wife’s (Mrs. bin Zhao) money?
Question#3: Is Biostage (BSTG) a majority Chinese owned through Private Placements and warrants executions with a minority U.S. investors managed from Beijing?
BUY the potential bouncers:
Applied Genetic Technologies (AGTC) closed down -$0.83 to $5.41 after Monday’s $6.24, Friday’s $7.03, Thursday’s $7.31 and last Wednesday’s $8.19 with a positive +$0.33 or +6.10% pre-market indication;
bluebird bio (BLUE) closed down again -$0.45 to $25.62 after Monday’s -$0.61 to $26.07, Friday’s -$0.27 to $26.88, Thursday’s -$1.07 to $26.95 with another positive +$0.88 or +3.43% pre-market indication.
CRISPR Therapeutics (CRSP) closed down -$3.26 to $135.30 after Monday’s $138.56, Friday’s $148.98, Thursday’s $146.66 and last Wednesday’s $150.03 with a positive +$6.20 or +4.58% pre-market indication;
Pluristem (PSTI) closed down -$0.34 to $6.48 after Friday’s $6.82 with a positive +$0.04 or +0.62% pre-market indication;
Mesoblast (MESO) closed down -$0.15 to $10.11 after Friday’s $10.26 with a positive +$0.17 or +1.68% pre-market indication.
Intellia Therapeutics (NTLA) closed down -$2.59 to $63.57 after Monday’s $66.16 with a positive +$1.13 or +1.78% pre-market indication. Earnings on Thursday …
SELL:
Solid Biosciences (SLDB) closed +$2.87 to $9.74 on WHAT (?) with a negative -$0.21 or -2.16% aftermarket indication.
Falling Knife:
Sage Therapeutics (SAGE) closed down again -$0.85 to $80.24 after Monday’s -$1.24 to $81.09, Friday’s +$3.86 to $82.33 and Friday’s -$4.01 to $78.47 with a negative -$0.24 or -0.33% pre-market indication. Earnings on Wednesday.
The BOTTOM LINE: Again, “forewarned … earnings LPS (loss-per-share) season is upon us – my advice, trim and skim … if one can!”
BUY those who have “reported” earnings … it’s STILL all about, the “bouncing ball” of sector momentum.
Many talk of horizons; “as I have said last week, my horizon is usually a Friday’s close …”
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
